1.4. References
[1] J. Ermann, C.G. Fathman, Autoimmune diseases: Genes, bugs and failed regulation, Nat. Immunol. 2 (2001) 759–761. https://doi.org/10.1038/ni0901-759.
[2] J. A. Hemler, E. J. Phillips, M. D, S. A. Mallal, M. B. B. S, P. L. Kendall, The Evolving Story of HLA and the Immunogenetics of Peanut Allergy, Ann Allergy Asthma Immunol. 115 (2015) 471-476. http://doi: 10. 1016/j.anai.2015.10.008
[3] K.M. Spach, F.E. Nashold, B.N. Dittel, C.E. Hayes, IL-10 Signaling Is Essential for 1,25-Dihydroxyvitamin D 3 -Mediated Inhibition of Experimental Autoimmune Encephalomyelitis , J. Immunol. 177 (2006) 6030–6037. https://doi.org/10.4049/jimmunol.177.9.6030.
[4] F.E. Nashold, K.A. Hoag, J. Goverman, C.E. Hayes, Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D3 prevention of experimental autoimmune encephalomyelitis, J. Neuroimmunol. 119 (2001) 16–29. https://doi.org/10.1016/S0165-5728(01)00360-5.
[5] T.P. Wypych, B.J. Marsland, Antibiotics as Instigators of Microbial Dysbiosis: Implications for Asthma and Allergy, Trends Immunol. 39 (2018) 697–711. https://doi.org/10.1016/j.it.2018.02.008.
[6] L.S.K. Walker, EFIS Lecture: Understanding the CTLA-4 checkpoint in the maintenance of immune homeostasis, Immunol. Lett. 184 (2017) 43–50. https://doi.org/10.1016/j.imlet.2017.02.007.
[7] D. Saadoun, M. Rosenzwajg, D. Landau, J.C. Piette, D. Klatzmann, P. Cacoub, Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis, Blood. 111 (2008) 5334–5341. https://doi.org/10.1182/blood-2007-11-122713.
[8] H. Tsujimoto, P.A. Efron, T. Matsumoto, R.F. Ungaro, A. Abouhamze, S. Ono, H. Mochizuki, L.L. Moldawer, Maturation of murine bone marrow-derived dendritic cells with poly(I:C) produces altered TLR-9 expression and response to CpG DNA, Immunol. Lett. 107 (2006) 155–162. https://doi.org/10.1016/j.imlet.2006.09.001.
[9] G. Hartmann, G.J. Weiner, A.M. Krieg, CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 9305–9310. https://doi.org/10.1073/pnas.96.16.9305.
[10] S. Schlickeiser, S. Stanojlovic, C. Appelt, K. Vogt, S. Vogel, S. Haase, T. Ritter, H.-D. Volk, U. Pleyer, B. Sawitzki, Control of TNF-Induced Dendritic Cell Maturation by Hybrid-Type N -Glycans , J. Immunol. 186 (2011) 5201–5211. https://doi.org/10.4049/jimmunol.1003410.
[11] J.R. Gordon, Y. Ma, L. Churchman, S.A. Gordon, W. Dawicki, Regulatory dendritic cells for immunotherapy in immunologic diseases, Front. Immunol. 5 (2014) 1–19. https://doi.org/10.3389/fimmu.2014.00007.
[12] H. Hasegawa, T. Matsumoto, Mechanisms of tolerance induction by dendritic cells in vivo, Front. Immunol. 9 (2018). https://doi.org/10.3389/fimmu.2018.00350.
[13] J. Ring, Davos Declaration: Allergy as a global problem, Allergy Eur. J. Allergy Clin. Immunol. 67 (2012) 141–143. https://doi.org/10.1111/j.1398- 9995.2011.02770.x.
[14] M. do C. Borralho, R.F. da Silva, A.S. Santana, R. de M. Caetano, Boas práticas da OMS para laboratórios de microbiologia farmacêutica de microbiologia farmacêutica, Série Rede Parf. 11 (2013) 1–37. https://doi.org/10.1016/j.jaut.2009.09.008.Recent.
[15] Japan intractable diseases information center, Transition data from 1975 to 2004, https://www.nanbyou.or.jp/entry/1356#p01
[16] M. Nishima, H. Odashima, K. Ota, N. Ota, K. Okazaki, M. Kanaya, N. Hisada, T. Kumamoto, T. Koga, N. Kobayashi, K. Satomi, Y. Shimada, M. Shimomura, M. Suda, I. Sunagawa, S.H. Osaka, Y. Nagata, T. Nakamura, K. Nishikawa, K. Hiraba, T. Fujino, T. Fujiwara, S. Honjo, T. Maeda, S. Matsumoto, T. Minami, Y. Miyazato, Prevalence Survey of Allergic Diseases in West Elementary School Children: Comparison in 1992, 2002, and 2012, Journal of Japanese Society of Pediatric Allergy, 27 (2013) 149-169, https://doi.org/10.3388/jspaci.27.149
[17] T.K. Kishimoto, R.A. Maldonado, Nanoparticles for the induction of antigenspecific immunological tolerance, Front. Immunol. 9 (2018). https://doi.org/10.3389/fimmu.2018.00230.
[18] R.A. Maldonado, R.A. LaMothe, J.D. Ferrari, A.H. Zhang, R.J. Rossi, P.N. Kolte, A.P. Griset, C. O’Neil, D.H. Altreuter, E. Browning, L. Johnston, O.C. Farokhzad, R. Langer, D.W. Scott, U.H. Von Andrian, T.K. Kishimoto, Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance, Proc. Natl. Acad. Sci. U. S. A. 112 (2015) E156–E165. https://doi.org/10.1073/pnas.1408686111.
[19] R.E. Ley, D.A. Peterson, J.I. Gordon, Ecological and evolutionary forces shaping microbial diversity in the human intestine, Cell. 124 (2006) 837–848. https://doi.org/10.1016/j.cell.2006.02.017.
[20] C. Bruhn, Wohngemeinschaft Haut, Dtsch. Apotheker Zeitung. 157 (2017) e1002. https://doi.org/10.1371/journal.pbio.1002533.
[21] P.J. Turnbaugh, R.E. Ley, M. Hamady, C.M. Fraser-Liggett, R. Knight, J.I. Gordon, The Human Microbiome Project, Nature. 449 (2007) 804–810. https://doi.org/10.1038/nature06244.
[22] D. Toor, M.K. Wasson, P. Kumar, G. Karthikeyan, N.K. Kaushik, C. Goel, S. Singh, A. Kumar, H. Prakash, Dysbiosis disrupts gut immune homeostasis and promotes gastric diseases, Int. J. Mol. Sci. 20 (2019) 1–14. https://doi.org/10.3390/ijms20102432.
[23] M. Yousaf, Inayatullah, A.R. Khan, N. Ahmad, S. Ali, The presentation pattern of otitis media with effusion, J. Med. Sci. 17 (2009) 53–55. https://doi.org/10.1126/scitranslmed.3009759.The.
[24] E.Y. Hsiao, S.W. McBride, S. Hsien, G. Sharon, E.R. Hyde, T. McCue, J.A. Codelli, J. Chow, S.E. Reisman, J.F. Petrosino, P.H. Patterson, S.K. Mazmanian, Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders, Cell. 155 (2013) 1451–1463. https://doi.org/10.1016/j.cell.2013.11.024.
[25] Q. Zhao, C.O. Elson, Adaptive immune education by gut microbiota antigens, Immunology. 154 (2018) 28–37. https://doi.org/10.1111/imm.12896.
[26] T. Tanoue, K. Atarashi, K. Honda, Development and maintenance of intestinal regulatory T cells, Nat. Rev. Immunol. 16 (2016) 295–309. https://doi.org/10.1038/nri.2016.36.
[27] K. Atarashi, T. Tanoue, K. Oshima, W. Suda, Y. Nagano, H. Nishikawa, S. Fukuda, T. Saito, S. Narushima, K. Hase, S. Kim, J. V. Fritz, P. Wilmes, S. Ueha, K. Matsushima, H. Ohno, B. Olle, S. Sakaguchi, T. Taniguchi, H. Morita, M. Hattori, K. Honda, Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota, Nature. 500 (2013) 232–236. https://doi.org/10.1038/nature12331.
[28] S.K. Lathrop, S.M. Bloom, S.M. Rao, K. Nutsch, C.W. Lio, N. Santacruz, D.A. Peterson, T.S. Stappenbeck, C.S. Hsieh, Peripheral education of the immune system by colonic commensal microbiota, Nature. 478 (2011) 250–254. https://doi.org/10.1038/nature10434.
[29] E. Blacher, M. Levy, E. Tatirovsky, E. Elinav, Microbiome-Modulated Metabolites at the Interface of Host Immunity, J. Immunol. 198 (2017) 572–580. https://doi.org/10.4049/jimmunol.1601247.
[30] L.E. Papanicolas, D.L. Gordon, S.L. Wesselingh, G.B. Rogers, Not Just Antibiotics: Is Cancer Chemotherapy Driving Antimicrobial Resistance?, Trends Microbiol. 26 (2018) 393–400. https://doi.org/10.1016/j.tim.2017.10.009.
[31] Y. and T.H. Belkaid, Role of the Microbiota in Immunity and inflammation Yasmine, Cell. 157 (2015) 121–141. https://doi.org/10.1016/j.cell.2014.03.011.Role.
[32] S.L. Russell, M.J. Gold, M. Hartmann, B.P. Willing, L. Thorson, M. Wlodarska, N. Gill, M.R. Blanchet, W.W. Mohn, K.M. McNagny, B.B. Finlay, Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma, EMBO Rep. 13 (2012) 440–447. https://doi.org/10.1038/embor.2012.32.
[33] S.L. Russell, M.J. Gold, B.P. Willing, L. Thorson, K.M. McNagny, B.B. Finlay, Perinatal antibiotic treatment affects murine microbiota, immune responses and allergic asthma, Gut Microbes. 4 (2013) 158–164. https://doi.org/10.4161/gmic.23567.
[34] M. Kaleko, J.A. Bristol, S. Hubert, T. Parsley, G. Widmer, S. Tzipori, P. Subramanian, N. Hasan, P. Koski, J. Kokai-Kun, J. Sliman, A. Jones, S. Connelly, Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection, Anaerobe. 41 (2016) 58–67. https://doi.org/10.1016/j.anaerobe.2016.05.015.
[35] T.O. Syn-, J.F. Kokai-kun, T. Roberts, O. Coughlin, E. Sicard, M. Rufiange, R. Fedorak, C. Carter, M.H. Adams, J. Longstreth, H. Whalen, crossm Clinical Studies, 61 (2017) 14–16.
[36] J. De Gunzburg, A. Ghozlane, A. Ducher, E. Le Chatelier, X. Duval, E. Ruppé, L. Armand-Lefevre, F. Sablier-Gallis, C. Burdet, L. Alavoine, E. Chachaty, V. Augustin, M. Varastet, F. Levenez, S. Kennedy, N. Pons, F. Mentré, A. Andremont, Protection of the human gut microbiome from antibiotics, J. Infect. Dis. 217 (2018) 628–636. https://doi.org/10.1093/infdis/jix604.
[37] C. Burdet, S. Sayah-Jeanne, T.T. Nguyen, C. Miossec, N. Saint-Lu, M. Pulse, W. Weiss, A. Andremont, F. Mentré, J. De Gunzburg, Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis, Antimicrob. Agents Chemother. 61 (2017) 1–9. https://doi.org/10.1128/AAC.00543-17.
2.5. References
[1] E.N. Grant, M. Robin Wagner, K.B. Weiss, Observations on emerging patterns of asthma in our society, J. Allergy Clin. Immunol. 104 (1999) 1–9. https://doi.org/10.1016/S0091-6749(99)70268-X.
[2] W.-J. Song, M.-G. Kang, Y.-S. Chang, S.-H. Cho, Epidemiology of adult asthma in Asia: toward a better understanding, Asia Pac. Allergy. 4 (2014) 75. https://doi.org/10.5415/apallergy.2014.4.2.75.
[3] M. Miyara, K. Wing, S. Sakaguchi, Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion, J. Allergy Clin. Immunol. 123 (2009) 749–755. https://doi.org/10.1016/j.jaci.2009.03.001.
[4] A. Schmidt, N. Oberle, P.H. Krammer, Molecular mechanisms oftreg-mediatedt cell suppression, Front. Immunol. 3 (2012) 1–20. https://doi.org/10.3389/fimmu.2012.00051.
[5] M. Caridade, L. Graca, R.M. Ribeiro, Mechanisms underlying CD4+ Treg immune regulation in the adult: From experiments to models, Front. Immunol. 4 (2013) 1– 9. https://doi.org/10.3389/fimmu.2013.00378.
[6] Y. Yu, X. Ma, R. Gong, J. Zhu, L. Wei, J. Yao, Recent advances in CD8+ regulatory t cell research (Review), Oncol. Lett. 15 (2018) 8187–8194. https://doi.org/10.3892/ol.2018.8378.
[7] S. Bézie, I. Anegon, C. Guillonneau, Advances on CD8+ Treg Cells and Their Potential in Transplantation, Transplantation. 102 (2018) 1467–1478. https://doi.org/10.1097/TP.0000000000002258.
[8] A. Schmidt, M. Eriksson, M.M. Shang, H. Weyd, J. Tegnér, Comparative analysis of protocols to induce human CD4+Foxp3+ regulatory T cells by combinations of IL-2, TGF-beta, retinoic acid, rapamycin and butyrate, PLoS One. 11 (2016) 1–31. https://doi.org/10.1371/journal.pone.0148474.
[9] J.R. Gordon, Y. Ma, L. Churchman, S.A. Gordon, W. Dawicki, Regulatory dendritic cells for immunotherapy in immunologic diseases, Front. Immunol. 5 (2014) 1–19. https://doi.org/10.3389/fimmu.2014.00007.
[10] R.A. Maldonado, R.A. LaMothe, J.D. Ferrari, A.H. Zhang, R.J. Rossi, P.N. Kolte, A.P. Griset, C. O’Neil, D.H. Altreuter, E. Browning, L. Johnston, O.C. Farokhzad, R. Langer, D.W. Scott, U.H. Von Andrian, T.K. Kishimoto, Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance, Proc. Natl. Acad. Sci. U. S. A. 112 (2015) E156–E165. https://doi.org/10.1073/pnas.1408686111.
[11] K. Zai, K. Yuzuriha, A. Kishimura, T. Mori, Y. Katayama, Preparation of complexes between ovalbumin nanoparticles and retinoic acid for efficient induction of Tolerogenic dendritic cells, Anal. Sci. 34 (2018) 1243–1248. https://doi.org/10.2116/analsci.18P252.
[12] T. Nikolic, B.O. Roep, Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin D3-treated tolerogenic dendritic cells, Front. Immunol. 4 (2013) 1–13. https://doi.org/10.3389/fimmu.2013.00113.
[13] G.B. Ferreira, C.A. Gysemans, J. Demengeot, J.P.M.C.M. da Cunha, A.-S. Vanherwegen, L. Overbergh, T.L. Van Belle, F. Pauwels, A. Verstuyf, H. Korf, C. Mathieu, 1,25-Dihydroxyvitamin D 3 Promotes Tolerogenic Dendritic Cells with Functional Migratory Properties in NOD Mice , J. Immunol. 192 (2014) 4210–4220. https://doi.org/10.4049/jimmunol.1302350.
[14] S. Agrawal, S. Ganguly, A. Tran, P. Sundaram, A. Agrawal, Retinoic acid treated human dendritic cells induce T regulatory cells via the expression of CD141 and GARP which is impaired with age, Aging (Albany. NY). 8 (2016) 1223–1235. https://doi.org/10.18632/aging.100973.
[15] G. Bakdash, L.T.C. Vogelpoel, T.M.M. Van Capel, M.L. Kapsenberg, E.C. De Jong, Retinoic acid primes human dendritic cells to induce gut-homing, IL-10- producing regulatory T cells, Mucosal Immunol. 8 (2015) 265–278. https://doi.org/10.1038/mi.2014.64.
[16] S.S. Cotrin, L. Puzer, W.A. De Souza Judice, L. Juliano, A.K. Carmona, M.A. Juliano, Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxydipeptidases: Assays with human cathepsin B, Anal. Biochem. 335 (2004) 244–252. https://doi.org/10.1016/j.ab.2004.09.012.
[17] G. Hook, J.S. Jacobsen, K. Grabstein, M. Kindy, V. Hook, Cathepsin B is a new drug target for traumatic brain injury therapeutics: Evidence for E64d as a promising lead drug candidate, Front. Neurol. 6 (2015) 1–27. https://doi.org/10.3389/fneur.2015.00178.
[18] G. Magoulas, D. Papaioannou, E. Papadimou, D. Drainas, Preparation of spermine conjugates with acidic retinoids with potent ribonuclease P inhibitory activity, Eur. J. Med. Chem. 44 (2009) 2689–2695. https://doi.org/10.1016/j.ejmech.2009.01.001.
[19] S. Patil, S. Gawali, S. Patil, S. Basu, Synthesis, characterization and in vitro evaluation of novel vitamin D3 nanoparticles as a versatile platform for drug delivery in cancer therapy, J. Mater. Chem. B. 1 (2013) 5742–5750. https://doi.org/10.1039/c3tb21176b.
[20] Z. Shen, G. Reznikoff, G. Dranoff, K.L. Rock, Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules., J. Immunol. 158 (1997) 2723–30. http://www.ncbi.nlm.nih.gov/pubmed/9058806.
[21] J.D. Pfeifer, M.J. Wick, R.L. Roberts, K. Findlay, S.J. Normark, C. V. Harding, Phagocytic processing of bacterial antigens for class I MHC presentation to T cells, Nature. 361 (1993) 359–362. https://doi.org/10.1038/361359a0.
[22] H. Sigmundsdottir, J. Pan, G.F. Debes, C. Alt, A. Habtezion, D. Soler, E.C. Butcher, DCs metabolize sunlight-induced vitamin D3 to “program” T cell attraction to the epidermal chemokine CCL27, Nat. Immunol. 8 (2007) 285–293. https://doi.org/10.1038/ni1433.
[23] W. Dawicki, C. Li, J. Town, X. Zhang, J.R. Gordon, Therapeutic reversal of food allergen sensitivity by mature retinoic acid–differentiated dendritic cell induction of LAG3+CD49b−Foxp3− regulatory T cells, J. Allergy Clin. Immunol. 139 (2017) 1608-1620.e3. https://doi.org/10.1016/j.jaci.2016.07.042.
[24] K.A. Wojtal, L. Wolfram, I. Frey-Wagner, S. Lang, M. Scharl, S.R. Vavricka, G. Rogler, The effects of vitamin A on cells of innate immunity in vitro, Toxicol. Vitr. 27 (2013) 1525–1532. https://doi.org/10.1016/j.tiv.2013.03.013.
[25] Y. Qiang, J. Xu, C. Yan, H. Jin, T. Xiao, N. Yan, L. Zhou, H. An, X. Zhou, Q. Shao, S. Xia, Butyrate and retinoic acid imprint mucosal-like dendritic cell development synergistically from bone marrow cells, Clin. Exp. Immunol. 189 (2017) 290–297. https://doi.org/10.1111/cei.12990.
[26] T. Feng, Y. Cong, H. Qin, E.N. Benveniste, C.O. Elson, Generation of Mucosal Dendritic Cells from Bone Marrow Reveals a Critical Role of Retinoic Acid, J. Immunol. 185 (2010) 5915–5925. https://doi.org/10.4049/jimmunol.1001233.
[27] L. Saurer, K.C. McCullough, A. Summerfield, In Vitro Induction of MucosaType Dendritic Cells by All- Trans Retinoic Acid , J. Immunol. 179 (2007) 3504– 3514. https://doi.org/10.4049/jimmunol.179.6.3504.
[28] D. Liang, A. Zuo, H. Shao, W.K. Born, R.L. O’Brien, H.J. Kaplan, D. Sun, Retinoic acid inhibits CD25+ dendritic cell expansion and γδ T-cell activation in experimental autoimmune uveitis., Invest. Ophthalmol. Vis. Sci. 54 (2013) 3493– 3503. https://doi.org/10.1167/iovs.12-11432.
[29] L. Abdelhamid, H. Hussein, M. Ghanem, N. Eissa, Retinoic acid-mediated antiinflammatory responses in equine immune cells stimulated by LPS and allogeneic mesenchymal stem cells, Res. Vet. Sci. 114 (2017) 225–232. https://doi.org/10.1016/j.rvsc.2017.05.006.
[30] H. Torres-Aguilar, M. Blank, L.J. Jara, Y. Shoenfeld, Tolerogenic dendritic cells in autoimmune diseases. Crucial players in induction and prevention of autoimmunity, Autoimmun. Rev. 10 (2010) 8–17. https://doi.org/10.1016/j.autrev.2010.07.015.
3.5. References
[1] L. Dethlefsen, D.A. Relman, Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 4554–4561. https://doi.org/10.1073/pnas.1000087107.
[2] C.M. Theriot, V.B. Young, Interactions Between the Gastrointestinal Microbiome and Clostridium difficile , Annu. Rev. Microbiol. 69 (2015) 445–461. https://doi.org/10.1146/annurev-micro-091014-104115.
[3] S. Burtion, N. Washington, R.J.C. Steele, R.M.A.L. Feely, Intragastric Distribution of Ion‐exchange Resins: a Drug Delivery System for the Topical Treatment of the Gastric Mucosa, J. Pharm. Pharmacol. 47 (1995) 901–906. https://doi.org/10.1111/j.2042-7158.1995.tb03268.x.
[4] Y. Belkaid, T.W. Hand, Role of the microbiota in immunity and inflammation, Cell. 157 (2014) 121–141. https://doi.org/10.1016/j.cell.2014.03.011.
[5] J. Harmoinen, K. Vaali, P. Koski, K. Syrjänen, O. Laitinen, K. Lindevall, E. Westermarck, Enzymic degradatoin of a β-lactam antibiotic, ampicillin, in the gut: A novel treatment modality, J. Antimicrob. Chemother. 51 (2003) 361–365. https://doi.org/10.1093/jac/dkg095.
[6] J. Harmoinen, S. Mentula, M. Heikkilä, M. Van Der Rest, P.J. Rajala-Schultz, C.J. Donskey, R. Frias, P. Koski, N. Wickstrand, H. Jousimies-Somer, E. Westermarck, K. Lindevall, Orally Administered Targeted Recombinant Beta-Lactamase Prevents Ampicillin-Induced Selective Pressure on the Gut Microbiota: A Novel Approach to Reducing Antimicrobial Resistance, Antimicrob. Agents Chemother. 48 (2004) 75–79. https://doi.org/10.1128/AAC.48.1.75-79.2004.
[7] U. Stiefel, J. Harmoinen, P. Koski, S. Kääriäinen, N. Wickstrand, K. Lindevall, N.J. Pultz, R.A. Bonomo, M.S. Helfand, C.J. Donskey, Orally administered recombinant metallo-β-lactamase preserves colonization resistance of piperacillintazobactam-treated mice [2], Antimicrob. Agents Chemother. 49 (2005) 5190– 5191. https://doi.org/10.1128/AAC.49.12.5190-5191.2005.
[8] A. Hoffman, E. Horwitz, S. Hess, R. Cohen-Poradosu, L. Kleinberg, A. Edelberg, M. Shapiro, Implications on emergence of antimicrobial resistance as a critical aspect in the design of oral sustained release delivery systems of antimicrobials, Pharm. Res. 25 (2008) 667–671. https://doi.org/10.1007/s11095-007-9373-6.
[9] J.F. Kokai-Kun, T. Roberts, O. Coughlin, C. Le, H. Whalen, R. Stevenson, V.J. Wacher, J. Sliman, Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial, Lancet Infect. Dis. 19 (2019) 487–496. https://doi.org/10.1016/S1473-3099(18)30731-X.
[10] J. De Gunzburg, A. Ghozlane, A. Ducher, E. Le Chatelier, X. Duval, E. Ruppé, L. Armand-Lefevre, F. Sablier-Gallis, C. Burdet, L. Alavoine, E. Chachaty, V. Augustin, M. Varastet, F. Levenez, S. Kennedy, N. Pons, F. Mentré, A. Andremont, Protection of the human gut microbiome from antibiotics, J. Infect. Dis. 217 (2018) 628–636. https://doi.org/10.1093/infdis/jix604.
[11] J. De Gunzburg, A. Ducher, C. Modess, D. Wegner, S. Oswald, J. Dressman, V. Augustin, C. Feger, A. Andremont, W. Weitschies, W. Siegmund, Targeted adsorption of molecules in the colon with the novel adsorbent-based Medicinal Product, DAV132: A proof of concept study in healthy subjects, J. Clin. Pharmacol. 55 (2015) 10–16. https://doi.org/10.1002/jcph.359.
[12] Y. Araki, T. Tsujikawa, A. Andoh, M. Sasaki, Y. Fujiyama, T. Bamba, Therapeutic effects of an oral adsorbent on acute dextran sulphate sodium-induced colitis and its recovery phase in rats, especially effects of elimination of bile acids in gut lumen, Dig. Liver Dis. 32 (2000) 691–698. https://doi.org/10.1016/S1590-8658(00)80332-1.
[13] Y. Liu, J. Coresh, J.A. Eustace, J.C. Longenecker, B. Jaar, N.E. Fink, R.P. Tracy, N.R. Powe, M.J. Klag, Association between Cholesterol Level and Mortality in Dialysis Patients: Role of Inflammation and Malnutrition, J. Am. Med. Assoc. 291 (2004) 451–459. https://doi.org/10.1001/jama.291.4.451.
[14] K. M. Wilson, Evaluating the Aaddition of Charcoals to Broiler Diets on the Recovery of Salmonella Typhimurium Grow-out and Processing, The University of Georgia, 2014, Master thesis Y. Liu, J. Coresh, J.A. Eustace, J.C. Longenecker, B. Jaar, N.E. Fink, R.P. Tracy, N.R. Powe, M.J. Klag, Association between Cholesterol Level and Mortality in Dialysis Patients: Role of Inflammation and Malnutrition, J. Am. Med. Assoc. 291 (2004) 451–459. https://doi.org/10.1001/jama.291.4.451.
[15] M. Khoder, N. Tsapis, V. Domergue-Dupont, C. Gueutin, E. Fattal, Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-pectinate beads, Eur. J. Pharm. Sci. 41 (2010) 281–288. https://doi.org/10.1016/j.ejps.2010.06.018.
[16] A.L. Halpin, T.J.B. de Man, C.S. Kraft, K.A. Perry, A.W. Chan, S. Lieu, J. Mikell, B.M. Limbago, L.C. McDonald, Intestinal microbiome disruption in patients in a long-term acute care hospital: A case for development of microbiome disruption indices to improve infection prevention, Am. J. Infect. Control. 44 (2016) 830–836. https://doi.org/10.1016/j.ajic.2016.01.003.
[17] L. Sun, X. Zhang, Y. Zhang, K. Zheng, Q. Xiang, N. Chen, Z. Chen, N. Zhang, J. Zhu, Q. He, Antibiotic-induced disruption of gut microbiota alters local metabolomes and immune responses, Front. Cell. Infect. Microbiol. 9 (2019) 1–13. https://doi.org/10.3389/fcimb.2019.00099.
[18] C.J. Donskey, M.S. Helfand, N.J. Pultz, L.B. Rice, Effect of Parenteral Fluoroquinolone Administration on Persistence of Vancomycin-Resistant Enterococcus faecium in the Mouse Gastrointestinal Tract, Antimicrob. Agents Chemother. 48 (2004) 326–328. https://doi.org/10.1128/AAC.48.1.326-328.2004.
[19] G.M. Sheldrick, P.G. Jones, O. Kennard, D.H. Williams, G.A. Smith, Structure of vancomycin and its complex with acetyl-D-alanyl-D-alanine, Nature. 271 (1978) 223–225. https://doi.org/10.1038/271223a0.
[20] R. Kannan, C.M. Harris, T.M. Harris, J.P. Waltho, N.J. Skelton, D.H. Williams, Function of the amino sugar and N-terminal amino acid of the antibiotic vancomycin in its complexation with cell wall peptides, J. Am. Chem. Soc. 110 (1988) 2946–2953. https://doi.org/10.1021/ja00217a042.
[21] V. Swali, N.J. Wells, G.J. Langley, M. Bradley, Solid-Phase Dendrimer Synthesis and the Generation of Super-High-Loading Resin Beads for Combinatorial Chemistry, J. Org. Chem. 62 (1997) 4902–4903. https://doi.org/10.1021/jo9708654.
[22] W.M. Cho, B.P. Joshi, H. Cho, K.H. Lee, Design and synthesis of novel antibacterial peptide-resin conjugates, Bioorganic Med. Chem. Lett. 17 (2007) 5772–5776. https://doi.org/10.1016/j.bmcl.2007.08.056.
[23] W.G. Gutheil, X.U. Qingchai, N-to-C solid-phase peptide and peptide trifluoromethylketone synthesis using amino acid tert-butyl esters, Chem. Pharm. Bull. 50 (2002) 688–691. https://doi.org/10.1248/cpb.50.688.
[24] G. Fischer, B. Wängler, C. Wängler, Optimized solid phase-assisted synthesis of dendrons applicable as scaffolds for radiolabeled bioactive multivalent compounds intended for molecular imaging, Molecules. 19 (2014) 6952–6974. https://doi.org/10.3390/molecules19066952.
[25] C. Schmidt, C. Lautenschlaeger, E.M. Collnot, M. Schumann, C. Bojarski, J.D. Schulzke, C.M. Lehr, A. Stallmach, Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa - A first in vivo study in human patients, J. Control. Release. 165 (2013) 139–145. https://doi.org/10.1016/j.jconrel.2012.10.019.
[26] M.J. Ahmed, Adsorption of quinolone, tetracycline, and penicillin antibiotics from aqueous solution using activated carbons: Review, Environ. Toxicol. Pharmacol. 50 (2017) 1–10. https://doi.org/10.1016/j.etap.2017.01.004.
[27] R. Jianghong, Y. Lin, L. Joydeep, G.M. Whitesides, R.M. Weis, H.S. Warren, Binding of a dimeric derivative of vancomycin to L-Lys-D-Ala-D-lactate in solution and at a surface, Chem. Biol. 6 (1999) 353–359. https://doi.org/10.1016/S1074-5521(99)80047-7.
[28] G.M. Hodges, E.A. Carr, R.A. Hazzard, K.E. Carr, Uptake and translocation of microparticles in small intestine - Morphology and quantification of particle distribution, Dig. Dis. Sci. 40 (1995) 967–975. https://doi.org/10.1007/BF02064184.
[29] P. Padmanabhan, J. Grosse, A.B.M.A. Asad, G.K. Radda, X. Golay, Gastrointestinal transit measurements in mice with 99mTc-DTPA-labeled activated charcoal using NanoSPECT-CT, EJNMMI Res. 3 (2013) 1. https://doi.org/10.1186/2191-219X-3-60.
[30] C. Walsh, 4 Walsh, 406 (2000) 775–781. www.nature.com.
[31] M.Y. Zeng, N. Inohara, G. Nuñez, Mechanisms of inflammation-driven bacterial dysbiosis in the gut, Mucosal Immunol. 10 (2017) 18–26. https://doi.org/10.1038/mi.2016.75.
[32] A.M. Seekatz, V.B. Young, Clostridium difficile and the microbiota, J. Clin. Invest. 124 (2014) 4182–4189. https://doi.org/10.1172/JCI72336.
[33] D.E. Freedberg, N.C. Toussaint, S.P. Chen, A.J. Ratner, S. Whittier, T.C. Wang, H.H. Wang, J.A. Abrams, Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial, Gastroenterology. 149 (2015) 883-885.e9. https://doi.org/10.1053/j.gastro.2015.06.043.
[34] L. Zhang, D. Dong, C. Jiang, Z. Li, X. Wang, Y. Peng, Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization, Anaerobe. 34 (2015) 1–7. https://doi.org/10.1016/j.anaerobe.2015.03.008.
[35] B. Chassaing, G. Srinivasan, M.A. Delgado, A.N. Young, A.T. Gewirtz, M. VijayKumar, Fecal Lipocalin 2, a Sensitive and Broadly Dynamic Non-Invasive Biomarker for Intestinal Inflammation, PLoS One. 7 (2012) 3–10. https://doi.org/10.1371/journal.pone.0044328.
論文の公開元へ
